Observing crystal-related arthritis conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to create an observatory for microcrystalline rheumatism, focusing on conditions like gout and chondrocalcinosis, at the Groupement des Hôpitaux de l'Institut Catholique de Lille. Patients already enrolled in a previous observational study will be included, along with new patients recruited during rheumatology consultations. Data on sociodemographic and clinical characteristics will be collected, and participants may undergo ultrasound and dual energy scanning for imaging. The study will track clinical and biological evolution over time to enhance understanding and management of these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of gout according to American College of Rheumatology /European League Against Rheumatism (ACR/EULAR) 2015 criteria OR diagnosis of calcium pyrophosphate dihydrate crystal deposition disease (CPPD) based on EULAR 2011 recommendations OR diagnosis of hydroxyapatite crystal rheumatism (HCR) according to a typical clinical sequence and demonstration of compatible calcium deposits on imaging
* patient who will benefit or has benefited from an ultrasound and/or DECT evaluation of microcrystalline deposits
* clinical suspicion of microcrystalline rheumatism requiring further imaging to confirm the diagnosis

Exclusion Criteria:

* Refusal or contra-indication to perform ultrasound or dual energy scanning.
* Patient's opposition to the use of his or her health data for research purposes
* Patient under guardianship or curatorship
* Pregnant woman
* Person not affiliated to a social security scheme or entitled to a social security benefit

Where it's running

• GHICL- Hôpital Saint Philibert
  Lomme, France Recruiting

Study contacts

• Principal investigator: Tristan Pascart, MD — Ghicl
• Study coordinator: Marie Paule LEBITASY, MD, PhD
• Email: lebitasy.marie-paule@ghicl.net
• Phone: 0033320225269

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment

  This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.

  Recruiting at 41 sites Phase 2 Crystalys Therapeutics · Birmingham, Alabama and 40 other locations · NCT07535034

• Orienting project on crystal deposits in gout, CPPD, and osteoarthritis

  This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Milano · NCT07504146

• Remote monitoring for gout in primary care

  This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.

  Recruiting Diakonhjemmet Hospital · Oslo · NCT07490522

• Purified Cortrophin® Gel for treating acute gout flares at two dose levels

  This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.

  Recruiting Phase 4 Massachusetts General Hospital · Boston, Massachusetts · NCT07346079

• IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout

  This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.

  Recruiting at 35 sites Phase 2 Protalix · Glendale, Arizona and 34 other locations · NCT07280156

• Dotinurad versus allopurinol for lowering uric acid in gout

  This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.

  Recruiting at 103 sites Phase 3 Crystalys Therapeutics · Birmingham, Alabama and 118 other locations · NCT07089875

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.